Eli Lilly stock gets FDA boost from weekly insulin approval evidence

Published on 09/26/2026 at 18:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eli Lilly stock closed at USD 1,184.38 on September 25 after FDA approval for weekly insulin. Q2 revenue rose 48 percent to USD 22.97 billion.

Extreme Makroaufnahme eines hochpolierten Edelstahlflanschs mit O-Ring-Dichtung einer Vakuumkammer auf schwarzem Hintergrund — Lam Research US5324571083 Makro polierter Vakuumkammer Flansch mit O Ring Dichtung auf schwarzem Hintergrund, Illustration mit AI erstellt.

Eli Lilly stock (ISIN US5324571083) closed at USD 1,184.38 on the NYSE on September 25, 2026, up 0.21 percent from the prior session. The latest catalyst is the FDA approval of Onswik, a once-weekly basal insulin for adults with type 2 diabetes, announced by Eli Lilly and Company on September 24, 2026.

Weekly insulin expands Lilly portfolio

Onswik is designed to provide steady basal insulin levels over seven days. The QWINT Phase 3 program supporting the approval enrolled more than 3,400 adults across four studies, and the treatment met its primary goal against daily basal insulins, according to Reuters on September 24, 2026. Lilly said the KwikPen will be available in the United States in the coming months.

Q2 growth meets a pricing test

Lilly reported adjusted second-quarter 2026 earnings per share of USD 8.38 against a Zacks consensus estimate of USD 6.01. Revenue reached USD 22.97 billion, up 48 percent year over year, while Mounjaro sales climbed 91 percent to USD 9.94 billion, according to Zacks on September 4, 2026. The counter-factor is pricing: net realized prices declined 13 percent in the quarter even as volumes increased 60 percent.

The company raised fiscal-year 2026 revenue guidance to USD 85 billion to USD 87 billion from USD 82 billion to USD 85 billion. Adjusted earnings guidance narrowed to USD 35.50 to USD 36.50 per share from USD 35.50 to USD 37.00, leaving execution and pricing central to the next phase of the growth story.

Analyst target reaches USD 1,400

Berenberg upgraded Lilly from Hold to Buy on September 15, 2026, and raised its price target from USD 1,220 to USD 1,400, citing obesity-market growth and expectations that Lilly can exceed its fiscal 2026 guidance, Yahoo Finance reported. The new target stands 18.2 percent above the September 25 closing price, while the stock remains USD 108.27 below its 52-week high of USD 1,292.65.

Stock stays near yearly high

Eli Lilly stock closed at USD 1,184.38 on the NYSE on September 25, 2026. The session range was USD 1,160.84 to USD 1,190.00, volume was 1,920,000 shares, and market capitalization stood at USD 1.1 trillion.